Sophia Genetics is a health technology company which develops SOPHiA artificial intelligence for clinical genomics used by healthcare institutions worldwide. The Company offers DRY LAB, an analytical solution for treating raw next-generation DNA sequencing (NGS) data; BUNDLE that offers enrichment kit and access to SOPHiA DDM platform; and integrated diagnostic solutions. It also provides SOPHiA DDM, a software-as-a-service platform that enables analysis and protection of clinical NGS data in the areas of oncology, metabolism, pediatrics, cardiology, and hereditary cancer.

Type
Private
HQ
Saint-Sulpice, CH
Founded
2011
Size (employees)
182 (est)+4%
Sophia Genetics was founded in 2011 and is headquartered in Saint-Sulpice, CH
Report incorrect company information

Key People/Management at Sophia Genetics

Jurgi Camblong

Jurgi Camblong

Chief Executive Officer and Co-Founder
Valentin Matillon

Valentin Matillon

CFO
Damien Lapray

Damien Lapray

Chief Commercial Officer
Marylin Schule

Marylin Schule

Chief Operations Officer
Didier Pitton

Didier Pitton

Chief Product Officer
Jasmine Beukema

Jasmine Beukema

VP Quality
Show more

Sophia Genetics Office Locations

Sophia Genetics has offices in Saint-Sulpice, Cambridgeshire and Montpellier
Saint-Sulpice, CH (HQ)
172 Rue du Centre
Montpellier, FR
55 Impasse Mac Gaffey
Cambridgeshire, GB
Cowley Rd
Show all (3)
Report incorrect company information

Sophia Genetics Financials and Metrics

Summary Metrics

Founding Date

2011

Total Funding

$58.8 m

Latest funding size

$30 m

Time since last funding

9 months ago

Investors

Sophia Genetics's latest funding round in September 2017 was reported to be $30 m. In total, Sophia Genetics has raised $58.8 m
Show all financial metrics
Report incorrect company information

Sophia Genetics Online and Social Media Presence

Embed Graph
Report incorrect company information

Sophia Genetics News and Updates

Swiss health tech company Sophia Genetics lands $30 mln Series D

Sophia Genetics, a Swiss health tech company, has secured $30 million in Series D funding. Balderton Capital led the round with participation from 360º Capital Partners, Invoke Capital and Alychlo.
Report incorrect company information